Efficacy, safety and cost-effectiveness of hydroxychloroquine in children with COVID-19: A call for evidence.
作者信息
Rodríguez-Martínez Carlos E, Fernandes Ricardo M, Hawcutt Daniel B, Sinha Ian P, Pacheco Rafael Leite
机构信息
Department of Pediatrics, School of Medicine, Universidad Nacional de Colombia, Bogota, Colombia.
Department of Pediatric Pulmonology and Pediatric Critical Care Medicine, School of Medicine, Universidad El Bosque, Bogota, Colombia.
出版信息
Acta Paediatr. 2020 Sep;109(9):1711-1712. doi: 10.1111/apa.15373. Epub 2020 Jun 3.
Abstract
摘要
相似文献
1
Efficacy, safety and cost-effectiveness of hydroxychloroquine in children with COVID-19: A call for evidence.羟氯喹啉治疗儿童新冠病毒肺炎的疗效、安全性及成本效益：证据呼吁
Acta Paediatr. 2020 Sep;109(9):1711-1712. doi: 10.1111/apa.15373. Epub 2020 Jun 3.
2
Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence.羟氯喹治疗新型冠状病毒肺炎：在等待确凿科学证据期间如何使用
Med Clin (Barc). 2020 Aug 14;155(3):134-135. doi: 10.1016/j.medcli.2020.05.006. Epub 2020 May 16.
3
Covid-19 treatment update: follow the scientific evidence.新冠病毒疾病治疗进展：遵循科学证据。
J Thromb Thrombolysis. 2020 Jul;50(1):43-53. doi: 10.1007/s11239-020-02120-9.
4
Hydroxychloroquine for Coronavirus: The Urgent Need for a Moratorium on Prescriptions.用于治疗冠状病毒的羟氯喹：迫切需要暂停处方使用
Am J Med. 2020 Sep;133(9):1007-1008. doi: 10.1016/j.amjmed.2020.05.005. Epub 2020 Jun 2.
5
Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.氯喹和羟氯喹用于治疗新型冠状病毒肺炎的安全性考量
Clin Microbiol Infect. 2020 Sep;26(9):1276-1277. doi: 10.1016/j.cmi.2020.05.006. Epub 2020 May 16.
6
Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19.氯喹和羟氯喹治疗 COVID-19 的紧急授权。
Ann Pharmacother. 2020 Aug;54(8):827-831. doi: 10.1177/1060028020925558. Epub 2020 May 9.
7
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.一项评估法匹拉韦和羟氯喹联合治疗中重度 COVID-19 住院成人的疗效和安全性的随机对照研究：研究方案的结构化总结。
Trials. 2020 Oct 31;21(1):904. doi: 10.1186/s13063-020-04825-x.
8
Why Your Patients' Believing Hydroxychloroquine and Chloroquine Are 90% Effective for COVID-19 Is 100% Dangerous.为何您的患者认为羟氯喹和氯喹对新冠病毒病有90%的疗效是极其危险的。
J Clin Pharmacol. 2020 Aug;60(8):949-953. doi: 10.1002/jcph.1687. Epub 2020 Jul 1.
9
Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base.羟氯喹在COVID-19危重症患者管理中的应用：循证依据的必要性。
Lancet Respir Med. 2020 Jun;8(6):539-541. doi: 10.1016/S2213-2600(20)30172-7. Epub 2020 Apr 15.
10
A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).氯喹和羟氯喹在冠状病毒病-19（COVID-19）中的预防作用的系统评价。
Int J Rheum Dis. 2020 May;23(5):613-619. doi: 10.1111/1756-185X.13842. Epub 2020 Apr 27.
引用本文的文献
1
-(2-Aminobenzoyl)benzotriazole Mediated Synthesis of 3-Acyl-2-alkyl(aryl)-4-hydroxyquinolines and 3-Acylamino-4(3) quinazolinones.-（2-氨基苯甲酰基）苯并三唑介导的3-酰基-2-烷基（芳基）-4-羟基喹啉和3-酰基氨基-4（3）喹唑啉酮的合成
Turk J Chem. 2023 Oct 16;48(1):97-107. doi: 10.55730/1300-0527.3642. eCollection 2024.
2
Therapeutic Strategies for COVID-19 Lung Disease in Children.儿童新冠病毒肺炎的治疗策略
Front Pediatr. 2022 Mar 7;10:829521. doi: 10.3389/fped.2022.829521. eCollection 2022.
3
Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients.氯喹和洛匹那韦/利托那韦对 COVID-19 治疗无效，联合使用会加重病情：重症患者的单中心经验。
Biomed Res Int. 2021 Feb 6;2021:8821318. doi: 10.1155/2021/8821318. eCollection 2021.
4
New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine.新型抗 SARS-CoV-2 靶点：氯喹和羟氯喹的喹啉衍生物。
Int J Mol Sci. 2020 Aug 14;21(16):5856. doi: 10.3390/ijms21165856.
本文引用的文献
1
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.药物治疗 2019 冠状病毒病（COVID-19）：综述。
JAMA. 2020 May 12;323(18):1824-1836. doi: 10.1001/jama.2020.6019.
2
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.氯喹、羟氯喹和阿奇霉素用于治疗新型冠状病毒肺炎（SARS-CoV-2感染）时的安全性考量
CMAJ. 2020 Apr 27;192(17):E450-E453. doi: 10.1503/cmaj.200528. Epub 2020 Apr 8.
3
Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries.氯喹和羟氯喹在治疗伴有或不伴有糖尿病的2019冠状病毒病中的应用：一项系统检索及叙述性综述，特别提及印度和其他发展中国家
Diabetes Metab Syndr. 2020 May-Jun;14(3):241-246. doi: 10.1016/j.dsx.2020.03.011. Epub 2020 Mar 26.
4
The isolation period should be longer: Lesson from a child infected with SARS-CoV-2 in Chongqing, China.隔离期应更长：来自中国重庆感染 SARS-CoV-2 儿童的教训。
Pediatr Pulmonol. 2020 Jun;55(6):E6-E9. doi: 10.1002/ppul.24763. Epub 2020 Apr 3.
5
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
6
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.羟氯喹啉是氯喹毒性较低的衍生物，在体外可有效抑制严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染。
Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.
7
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
8
The Role of Intuition in Risk/Benefit Decision-Making in Human Subjects Research.直觉在人体研究风险/收益决策中的作用
Account Res. 2017;24(1):1-29. doi: 10.1080/08989621.2016.1198978. Epub 2016 Jun 13.
9
Hydroxychloroquine: from malaria to autoimmunity.羟氯喹：从疟疾到自身免疫。
Clin Rev Allergy Immunol. 2012 Apr;42(2):145-53. doi: 10.1007/s12016-010-8243-x.
Zotero 插件